BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Safety Findings from Clinical Trial of Concussion Drug

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, has completed the safety evaluation for cohort 1 of its phase 1 clinical trial, which is being conducted by Nucleus Network, a leading clinical research organization. The trial studies the treatment of concussions in healthy human subjects using the company’s novel PRV-002. The company noted that the safety findings were positive and the drug was safe and well tolerated. According to the announcement, cohort 1 comprised eight healthy human volunteers who were administered a dose of PRV-002 or placebo then watched for responses. The company noted that no severe adverse events were recorded and all vital signs, EKG readings, sleep patterns and breathing function were normal. The phase I clinical trial, which includes 40 healthy participants, is ongoing; the company will continue to report additional results. “After reviewing the data from this cohort, I have strong confidence that PRV-002 will continue to show safety for this phase I clinical trial as an option for the treatment of concussion,” said Dallas Hack, MD, a member of the Safety Review Committee, in the press release. “No abnormalities were seen, and we have unanimously approved the next cohort where the treatment dose will be increased. I look forward to completing the phase I trial and assisting Odyssey in presenting these safety findings to the FDA.”

To view the full press release, visit https://ibn.fm/sDNlN

About Odyssey Health Inc. 

Odyssey Health Inc., formerly Odyssey Group International, is a technology and asset acquisition company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and accumulate distinct assets, intellectual property and exceptional technologies that provide meaningful medical solutions. The company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.

 NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork